Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huolingshengji Keli granules versus riluzole in amyotrophic lateral sclerosis
ChiCTR2100044085Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Huoling Shengji Granules and riluzole in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Change from baseline in ALS Functional Rating Scale-Revised score. Started Apr 2020; status: recruiting.
02
Drugs
Huoling Shengji Granulesriluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2100044085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044085.